Table of contents PDF

Contents
The Eular Journal
Editorial
321
Volume 74 Issue 2 | ARD February 2015
381
Psoriasis, psoriatic arthritis and cardiovascular risk: are
we closer to a clinical recommendation?
A-B Aga, E Lie, T Uhlig, I C Olsen, A Wierød, S Kalstad,
E Rødevand, K Mikkelsen, T K Kvien, E A Haavardsholm
S L Kristensen, I B McInnes, N Sattar
Viewpoint
323
Statistical review: frequently given comments
Time trends in disease activity, response and remission
rates in rheumatoid arthritis during the past decade:
results from the NOR-DMARD study 2000–2010
389
OPEN ACCESS
S Lydersen
Discontinuation of adalimumab after achieving
remission in patients with established rheumatoid
arthritis: 1-year outcome of the HONOR study
Y Tanaka, S Hirata, S Kubo, S Fukuyo, K Hanami,
N Sawamukai, K Nakano, S Nakayamada, K Yamaoka,
F Sawamura, K Saito
Clinical and epidemiological research
326
Editor
Associate Editors
333
OPEN ACCESS
Disclaimer: ARD is owned and published by
BMJ Publishing Group Ltd (a wholly owned
subsidiary of the British Medical Association)
and the European League Against Rheumatism. The
owners grant editorial freedom tothe Editor of ARD.
ARD follows guidelines on editorial independence
produced by the World Association of Medical Editors
and the code on good publication practice ofthe
Committee on Publication Ethics.
ARD is intended for medical professionals and is
provided without warranty, express or implied.
Statements in the journal are the responsibility
of their authors and advertisers and not authors’
institutions the BMJ Publishing Group, the
European League Against Rheumatism or the
BMA unless otherwise specifi ed or determined
by law. Acceptance of advertising does not imply
endorsement.
To the fullest extent permitted by law, the BMJ
Publishing Group shall not be liable for any loss, injury
or damage resulting from the use of ARD or any
information in it whether based on contract, tort, or
otherwise. Readers are advised to verify any
information they choose to rely on.
Copyright: © 2015 BMJ Publishing Group and
European League Against Rheumatism. All rights
reserved; no part of this publication may be reproduced
stored in a retrieval system, or transmitted in any form
or by any means, electronic, mechanical, photocopying
recording, or otherwise without prior permission
ARD is published by BMJ Publishing Group Ltd typeset
by Techset and printed in the UK on acid-free paper.
Annals of the Rheumatic Diseases (ISSN No:
0003-4967) is published monthly by BMJ Publishing
Group and distributed in the USA by Air Business Ltd.
Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to Annals of the
Rheumatic Diseases, Air Business Ltd, c/o Worldnet
Shipping Inc., 156-15, 146th Avenue, 2nd Floor,
Jamaica, NY 11434, USA.
Safety and efficacy of baricitinib at 24 weeks in
patients with rheumatoid arthritis who have had an
inadequate response to methotrexate
K V C Wevers-de Boer, L Heimans, K Visser, J Kälvesten,
R J Goekoop, M van Oosterhout, J B Harbers, C Bijkerk,
M Steup-Beekman, M P D M de Buck, P B J de Sonnaville,
T W J Huizinga, C F Allaart
347
Worsening of pain and function over 5 years in
individuals with ‘early’ OA is related to structural
damage: data from the Osteoarthritis Initiative and
CHECK (Cohort Hip & Cohort Knee) study
J Wesseling, S M A Bierma-Zeinstra, M Kloppenburg,
R Meijer, J W J Bijlsma
354
OPEN ACCESS
Methotrexate polyglutamates in erythrocytes are
associated with lower disease activity in juvenile
idiopathic arthritis patients
M B C´alasan, E den Boer, M C F J de Rotte, S J Vastert,
S Kamphuis, R de Jonge, N M Wulffraat
Four-month metacarpal bone mineral density loss
predicts radiological joint damage progression after
1 year in patients with early rheumatoid arthritis:
exploratory analyses from the IMPROVED study
Methotrexate polyglutamates in erythrocytes are
associated with lower disease activity in patients with
rheumatoid arthritis
M C F J de Rotte, E den Boer, P H P de Jong, S M F Pluijm,
M B C´alasan, A E Weel, A M Huisman, A H Gerards,
B van Schaeybroeck, N M Wulffraat, J Lindemans,
J M W Hazes, R de Jonge
415
OPEN ACCESS
Mortality in rheumatoid arthritis: the impact of disease
activity, treatment with glucocorticoids, TNF␣ inhibitors
and rituximab
J Listing, J Kekow, B Manger, G-R Burmester, D Pattloch,
A Zink, A Strangfeld
422
Drug survival on TNF inhibitors in patients with
rheumatoid arthritis comparison of adalimumab,
etanercept and infliximab
Disease-modifying effect of strontium ranelate in a
subset of patients from the Phase III knee osteoarthritis
study SEKOIA using quantitative MRI: reduction in bone
marrow lesions protects against cartilage loss
J-P Pelletier, C Roubille, J-P Raynauld, F Abram, M Dorais,
P Delorme, J Martel-Pelletier
M Neovius, E V Arkema, H Olsson, J K Eriksson,
L E Kristensen, J F Simard, J Askling, for the ARTIS Study
Group
361
Personalised treatment using serum drug levels of
adalimumab in patients with rheumatoid arthritis: an
evaluation of costs and effects
C L M Krieckaert, S C Nair, M T Nurmohamed,
C J J van Dongen, W F Lems, F P J G Lafeber, J W J Bijlsma,
H Koffijberg, G Wolbink, P M J Welsing
369
OPEN ACCESS
C-F Kuo, M J Grainge, L-C See, K-H Yu, S-F Luo,
A M Valdes, W Zhang, M Doherty
375
MORE CONTENTS 䉴
This article has been chosen by the Editor to be of special interest
or importance and is freely available online.
Familial aggregation of gout and relative genetic and
environmental contributions: a nationwide population
study in Taiwan
Environmental and genetic factors in the development
of anticitrullinated protein antibodies (ACPAs) and
ACPA-positive rheumatoid arthritis: an epidemiological
investigation in twins
A H Hensvold, P K E Magnusson, V Joshua, M Hansson,
L Israelsson, R Ferreira, P-J Jakobsson, R Holmdahl,
L Hammarström, V Malmström, J Askling, L Klareskog,
A I Catrina
Receive regular table of contents by email.
Register using this QR code.
402
408
341
Immunogenicity, adalimumab levels and clinical
response in ankylosing spondylitis patients during
24 weeks of follow-up
E L Kneepkens, J C-C Wei, M T Nurmohamed, K-J Yeo,
C Y Chen, I E van der Horst-Bruinsma, D van der Kleij,
T Rispens, G Wolbink, C L M Krieckaert
E C Keystone, P C Taylor, E Drescher, D E Schlichting,
S D Beattie, P-Y Berclaz, C H Lee, R K Fidelus-Gort,
M E Luchi, T P Rooney, W L Macias, M C Genovese
Editorial office
Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WCIH 9JR,UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.270
396
A Ogdie, Y D Yu, K Haynes, T J Love, S Maliha, Y Jiang,
A B Troxel, S Hennessy, S E Kimmel, D J Margolis, H Choi,
N N Mehta, J M Gelfand
Tore K Kvien
Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
Risk of major cardiovascular events in patients with
psoriatic arthritis, psoriasis and rheumatoid arthritis:
a population-based cohort study
OPEN ACCESS
This article has been made freely available online under the BMJ
Journals Open Access scheme.
See http://ard.bmj.com/site/about/guidelines.xhtml#open
This journal is a member of and subscribes to the principles of the
Committee on Publication Ethics
http://publicationethics.org/
Contents
430
OPEN ACCESS
The comparative effectiveness of abatacept versus
anti-tumour necrosis factor switching for rheumatoid
arthritis patients previously treated with an anti-tumour
necrosis factor
Volume 74 Issue 2 | ARD February 2015
Letters
470
L R Harrold, G W Reed, J M Kremer, J R Curtis, D H Solomon,
M C Hochberg, J D Greenberg
437
Quantitative syndesmophyte measurement in
ankylosing spondylitis using CT: longitudinal validity
and sensitivity to change over 2 years
T van den Broek, E Hoppenreijs, J Meerding, R Scholman,
H G Otten, J F Swart, A Martini, B Prakken, W de Jager
472
S Tan, J Yao, J A Flynn, L Yao, M M Ward
Anti-inflammatory effects of cell-based therapy with
tyrosine hydroxylase-positive catecholaminergic cells in
experimental arthritis
474
Z Jenei-Lanzl, S Capellino, F Kees, M Fleck, T Lowin, R H Straub
452
Cathepsin S inhibition suppresses systemic lupus
erythematosus and lupus nephritis because cathepsin
S is essential for MHC class II-mediated CD4 T cell and
B cell priming
K V Rupanagudi, O P Kulkarni, J Lichtnekert,
M N Darisipudi, S R Mulay, B Schott, S Gruner, W Haap,
G Hartmann, H-J Anders
TNF␣ regulates cortisol metabolism in vivo in patients
with inflammatory arthritis
D E Nanus, A D Filer, B Hughes, B A Fisher, P C Taylor,
P M Stewart, C D Buckley, I McInnes, M S Cooper, K Raza
Adalimumab trough concentrations in patients with
rheumatoid arthritis and psoriatic arthritis treated with
concomitant disease-modifying antirheumatic drugs
E H Vogelzang, M F Pouw, M Nurmohamed,
E L Kneepkens, T Rispens, G J Wolbink, C L M Krieckaert
475
The EULAR Outcome Measures Library: an evolutional
database of validated patient-reported instruments
I Castrejón, L Gossec, L Carmona
Correction
476
464
The effect of mindfulness-based stress reduction on
disease activity in people with rheumatoid arthritis:
a randomised controlled trial
F A Fogarty, R J Booth, G D Gamble, N Dalbeth,
N S Consedine
Basic and translational research
444
Cytokine profiling at disease onset: support for
classification of young antinuclear antibody-positive
patients as a separate category of juvenile idiopathic
arthritis
Correction
Electronic page
e11
Thank you to our reviewers 2014